Editas Medicine, Inc. (0IFK.L)
USD 1.29
(0.78%)
USD 1.29
(0.78%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 24.37 Million USD | -25.84% |
| 2022 | 32.86 Million USD | 104.52% |
| 2021 | 16.06 Million USD | -16.84% |
| 2020 | 19.32 Million USD | -16.98% |
| 2019 | 23.27 Million USD | -28.2% |
| 2018 | 32.41 Million USD | -3.03% |
| 2017 | 33.43 Million USD | -4.74% |
| 2016 | 35.09 Million USD | -82.44% |
| 2015 | 199.91 Million USD | 58014.83% |
| 2014 | 344 Thousand USD | -83.7% |
| 2013 | 2.11 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 20.51 Million USD | 0.0% |
| 2024 Q1 | 21.78 Million USD | 0.0% |
| 2024 Q3 | 22.09 Million USD | 0.0% |
| 2023 Q2 | 26.85 Million USD | -6.78% |
| 2023 Q3 | 24.91 Million USD | -7.22% |
| 2023 Q4 | 24.37 Million USD | -2.19% |
| 2023 FY | 24.37 Million USD | -25.84% |
| 2023 Q1 | 28.81 Million USD | -12.34% |
| 2022 FY | 32.86 Million USD | 104.52% |
| 2022 Q4 | 32.86 Million USD | 252.32% |
| 2022 Q3 | 9.32 Million USD | -7.73% |
| 2022 Q2 | 10.11 Million USD | -21.97% |
| 2022 Q1 | 12.95 Million USD | -19.37% |
| 2021 Q2 | 21.28 Million USD | -1.57% |
| 2021 Q1 | 21.62 Million USD | 11.89% |
| 2021 Q3 | 18.43 Million USD | -13.4% |
| 2021 Q4 | 16.06 Million USD | -12.81% |
| 2021 FY | 16.06 Million USD | -16.84% |
| 2020 Q1 | 21.53 Million USD | -7.51% |
| 2020 Q2 | 22.15 Million USD | 2.89% |
| 2020 Q3 | 20.36 Million USD | -8.06% |
| 2020 FY | 19.32 Million USD | -16.98% |
| 2020 Q4 | 19.32 Million USD | -5.13% |
| 2019 FY | 23.27 Million USD | -28.2% |
| 2019 Q3 | 13.2 Million USD | -4.22% |
| 2019 Q2 | 13.78 Million USD | -7.23% |
| 2019 Q1 | 14.85 Million USD | -54.16% |
| 2019 Q4 | 23.27 Million USD | 76.31% |
| 2018 Q2 | 32.94 Million USD | -0.74% |
| 2018 Q3 | 32.69 Million USD | -0.76% |
| 2018 FY | 32.41 Million USD | -3.03% |
| 2018 Q4 | 32.41 Million USD | -0.85% |
| 2018 Q1 | 33.19 Million USD | -0.72% |
| 2017 Q3 | 33.66 Million USD | -0.62% |
| 2017 FY | 33.43 Million USD | -4.74% |
| 2017 Q1 | 33.92 Million USD | -3.33% |
| 2017 Q2 | 33.87 Million USD | -0.15% |
| 2017 Q4 | 33.43 Million USD | -0.7% |
| 2016 Q3 | 32.04 Million USD | 41.33% |
| 2016 Q4 | 35.09 Million USD | 9.51% |
| 2016 Q2 | 22.67 Million USD | 94.66% |
| 2016 Q1 | 11.64 Million USD | -94.17% |
| 2016 FY | 35.09 Million USD | -82.44% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 199.91 Million USD | 58014.83% |
| 2015 Q4 | 199.91 Million USD | 14407.62% |
| 2015 Q3 | 1.37 Million USD | 56.77% |
| 2015 Q2 | 879 Thousand USD | 0.0% |
| 2014 Q4 | 344 Thousand USD | 0.0% |
| 2014 FY | 344 Thousand USD | -83.7% |
| 2013 FY | 2.11 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | 81.262% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 93.716% |
| Dynavax Technologies Corporation | 252.41 Million USD | 90.345% |
| Illumina, Inc. | 1.48 Billion USD | 98.363% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.812% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 90.564% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.922% |
| Biogen Inc. | 7.18 Billion USD | 99.661% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 57.233% |
| bluebird bio, Inc. | 224.41 Million USD | 89.14% |
| Imunon, Inc. | 1.13 Million USD | -2039.221% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 98.766% |
| Myriad Genetics, Inc. | 130.9 Million USD | 81.381% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 97.848% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 26.582% |
| Nektar Therapeutics | 112.62 Million USD | 78.36% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 34.27% |
| Perrigo Company plc | 3.63 Billion USD | 99.329% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 46.661% |
| Verastem, Inc. | 40.08 Million USD | 39.201% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.697% |
| Waters Corporation | 2.3 Billion USD | 98.943% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -652.54% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -2337.2% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 85.973% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -3.539% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 95.891% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 27.28% |
| Evolus, Inc. | 120.35 Million USD | 79.751% |
| Adicet Bio, Inc. | 17.7 Million USD | -37.672% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -692.843% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.098% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 95.141% |
| FibroGen, Inc. | 89.69 Million USD | 72.829% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.109% |
| OPKO Health, Inc. | 222.03 Million USD | 89.023% |
| Homology Medicines, Inc. | 43.17 Million USD | 43.552% |
| Geron Corporation | 35.05 Million USD | 30.467% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.96% |
| Exelixis, Inc. | 189.94 Million USD | 87.169% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -2503.846% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 74.809% |
| Zoetis Inc. | 6.56 Billion USD | 99.629% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 86.313% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -453.657% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 96.637% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 28.716% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 98.26% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.374% |
| Blueprint Medicines Corporation | 610.96 Million USD | 96.011% |
| Insmed Incorporated | 1.19 Billion USD | 97.958% |
| TG Therapeutics, Inc. | 100.11 Million USD | 75.657% |
| Incyte Corporation | 29.16 Million USD | 16.425% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 94.542% |